Inhibition of prostate cancer growth by vitamin D: Regulation of target gene expression

Journal of Cellular Biochemistry

Volumn 88, Issue 2, 2003, Pages 363-371

  Krishnan, Aruna V ^a   Peehl, Donna M ^a   Feldman, David ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

1,25 dihydroxyvitamin D3; 24 hydroxylase(cDNA microarray; IGFBP 3; Vitamin D receptor

Indexed keywords

25 HYDROXYCOLECALCIFEROL 24 HYDROXYLASE; CALCIDIOL 1 MONOOXYGENASE; CALCIFEDIOL; CALCITRIOL; COMPLEMENTARY DNA; OXYGENASE; PROSTATE SPECIFIC ANTIGEN; SOMATOMEDIN BINDING PROTEIN 3; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN D RECEPTOR;

ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CATALYSIS; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONFERENCE PAPER; DNA MICROARRAY; DRUG EFFECT; DRUG MECHANISM; GENE CONTROL; GENE EXPRESSION; GENE TARGETING; HUMAN; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SYNTHESIS;

25-HYDROXYVITAMIN D3 1-ALPHA-HYDROXYLASE; ANDROGENS; ANIMALS; CALCITRIOL; CELL DIVISION; CLINICAL TRIALS; CYTOCHROME P-450 ENZYME SYSTEM; GENE EXPRESSION REGULATION; HUMANS; MALE; PROSTATIC NEOPLASMS; STEROID HYDROXYLASES; VITAMIN D;

EID: 8844273350     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcb.10334     Document Type: Conference Paper

References (49)

1. Blutt SE, Weigel NL. 1999. Vitamin D and prostate cancer. Proc Soc Exp Biol Med 221:89-98.
2. Blutt SE, Allegretto EA, Pike JW, Weigel NL. 1997. 1,25-Dihydroxyvitamin D3 and 9-cis-retinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G1. Endocrinology 138:1491-1497.
3. Blutt SE, McDonnell TJ, Polek TC, Weigel NL. 2000. Calcitriol-induced apoptosis in LNCaP cells is blocked by overexpression of Bcl-2. Endocrinology 141:10-17.
4. Bookstein R, Shew JY, Chen PL, Scully P, Lee WH. 1990. Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene. Science 247:712-715.
5. 3 growth inhibition in the LNCaP prostate cancer cell line through p21/WAF1. J Urol 165:1319-1324.
6. Campbell MJ, Elstner E, Holden S, Uskokovic M, Koeffler HP. 1997. Inhibition of proliferation of prostate cancer cells by a 19-nor-hexafluoride vitamin D3 analogue involves the induction of p21waf1, p27kip1, and E-cadherin. J Mol Endocrinol 19:15-27.
7. Drivdahl RH, Loop SM, Andress DL, Ostenson RC. 1995. IGF-binding proteins in human prostate tumor cells: Expression and regulation by 1,25-dihydroxyvitamin D3. Prostate 26:72-79.
8. Feldman D. 1997. Androgen and vitamin D receptor gene polymorphisms: The long and short of prostate cancer risk. J Natl Cancer Inst 89:109-111.
9. Feldman BJ, Feldman D. 2001. The development of androgen-independent prostate cancer. Nat Rev Cancer 1:34-45.
10. Feldman D, Glorieux FH, Pike JW. 1997. Vitamin D. San Diego: Academic Press. pp 1-1285.
11. Feldman D, Zhao XY, Krishnan AV. 2000. Vitamin D and prostate cancer. Endocrinology 141:5-9.
12. Feldman D, Malloy PJ, Gross C. 2001. Vitamin D: Biology, action, and clinical implications. In: Marcus R, Feldman D, Kelsey J, editors. Osteoporosis. San Diego: Academic Press. pp 257-303.
13. Freedman LP. 1999. Transcriptional targets of the vitamin D3 receptor-mediating cell cycle arrest and differentiation. J Nutr 129:581S-586S.
14. Gross C, Peehl DM, Feldman D. 1997. Vitamin D and prostate cancer. In: Feldman D, Glorieux FH, Pike JW, editors. Vitamin D. San Diego: Academic Press. pp 1125-1139.
15. Gross C, Stamey T, Hancock S, Feldman D. 1998. Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol). J Urol 159:2035-2039; discussion 2039-2040.
16. Hansen CM, Frandsen TL, Brunner N, Binderup L. 1994.1 alpha,25-Dihydroxyvitamin D3 inhibits the invasive potential of human breast cancer cells in vitro. Clin Exp Metastasis 12:195-202.
17. Hellerstedt BA, Pienta KJ. 2002. The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 52:154-179.
18. Hisatake J, Kubota T, Hisatake Y, Uskokovic M, Tomoyasu S, Koeffler HP. 1999. 5,6-trans-16-ene-vitamin D3: A new class of potent inhibitors of proliferation of prostate, breast, and myeloid leukemic cells. Cancer Res 59:4023-4029.
19. Hsu JY, Feldman D, McNeal JE, Peehl DM. 2001. Reduced 1alpha-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-induced growth inhibition. Cancer Res 61:2852-2856.
20. 3 and its analog EB 1089. Int J Oncol 13:137-143.
21. Ingles SA, Coetzee GA, Ross RK, Henderson BE, Kolonel LN, Crocitto L, Wang W, Haile RW. 1998. Association of prostate cancer with vitamin D receptor haplotypes in African-Americans. Cancer Res 58:1620-1623.
22. Jurutka PW, Remus LS, Whitfield GK, Thompson PD, Hsieh JC, Zitzer H, Tavakkoli P, Galligan MA, Dang HT, Haussler CA, Haussler MR. 2000. The polymorphic N terminus in human vitamin D receptor isoforms influences transcriptional activity by modulating interaction with transcription factor IIB. Mol Endocrinol 14:401-420.
23. Kivineva M, Blauer M, Syvala H, Tammela T, Tuohimaa P. 1998. Localization of 1,25-dihydroxyvitamin D3 receptor (VDR) expression in human prostate. J Steroid Biochem Mol Biol 66:121-127.
24. Konety BR, Schwartz GG, Acierno JS, Jr., Becich MJ, Getzenberg RH. 1996. The role of vitamin D in normal prostate growth and differentiation. Cell Growth Differ 7:1563-1570.
25. Konety BR, Johnson CS, Trump DL, Getzenberg RH. 1999. Vitamin D in the prevention and treatment of prostate cancer. Semin Urol Oncol 17:77-84.
26. Liu M, Lee MH, Cohen M, Bommakanti M, Freedman LP. 1996. Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev 10:142-153.
27. Lucia MS, Bostwick DG, Bosland M, Cockett AT, Knapp DW, Leav I, Pollard M, Rinker-Schaeffer C, Shirai T, Watkins BA. 1998. Workgroup I: Rodent models of prostate cancer. Prostate 36:49-55.
28. Ly LH, Zhao XY, Holloway L, Feldman D. 1999. Liarozole acts synergistically with 1alpha,25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity. Endocrinology 140:2071-2076.
29. Majewski S, Skopinska M, Marczak M, Szmurlo A, Bollag W, Jablonska S. 1996. Vitamin D3 is a potent inhibitor of tumor cell-induced angiogenesis. J Investig Dermatol Symp Proc 1:97-101.
30. Mantell DJ, Owens PE, Bundred NJ, Mawer EB, Canfield AE. 2000. 1 alpha,25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo, Circ Res 87:214-220.
31. Miller G. 1999. Vitamin D and prostate cancer: Biological interactions and clinical potentials. Cancer Met Rev 17:353-360.
32. Miller GJ, Stapleton GE, Ferrara JA, Lucia MS, Pfister S, Hedlund TE, Upadhya P. 1992. The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1 alpha,25-dihydroxyvitamin D3. Cancer Res 52:515-520.
33. Miller GJ, Stapleton GE, Hedlund TE, Moffat KA. 1995. Vitamin D receptor expression, 24-hydroxylase activity, and inhibition of growth by 1alpha,25-dihydroxyvitamin D3 in seven human prostatic carcinoma cell lines. Clin Cancer Res 1:997-1003.
34. Osborn JL, Schwartz GG, Smith DC, Bahnson RR, Day R, Trump DL. 1995. Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer. Urol Oncol 1:195-198.
35. Peehl DM, Skowronski RJ, Leung GK, Wong ST, Stamey TA, Feldman D. 1994. Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res 54:805-810.
36. Peehl DM, Seto E, Hsu JY, Feldman D. 2002. Preclinical activity of ketoconazole in combination with calcitriol or the vitamin D analog EB 1089 on prostate cancer cells. J Urol 168:1583-1588.
37. Schwartz GG, Hulka BS. 1990. Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res 10:1307-1311.
38. Schwartz GG, Hill CC, Oeler TA, Becich MJ, Bahnson RR. 1995. 1,25-Dihydroxy-16-ene-23-yne-vitamin D3 and prostate cancer cell proliferation in vivo. Urology 46:365-369.
39. Schwartz GG, Whitlatch LW, Chen TC, Lokeshwar BL, Holick MF. 1998. Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3. Cancer Epidemiol Biomarkers Prev 7:391-395.
40. Schwartz Z, Sylvia VL, Larsson D, Nemere I, Casasola D, Dean DD, Boyan BD. 2002. 1alpha,25(OH)2D3 regulates chondrocyte matrix vesicle protein kinase C (PKC) directly via G-protein-dependent mechanisms and indirectly via incorporation of PKC during matrix vesicle biogenesis. J Biol Chem 277:11828-11837.
41. Skowronski RJ, Peehl DM, Feldman D. 1993. Vitamin D and prostate cancer: 1,25 Dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology 132:1952-1960.
42. Sung V, Feldman D. 2000. 1,25-Dihydroxyvitamin D3 decreases human prostate cancer cell adhesion and migration. Mol Cell Endocrinol 164:133-143.
43. Uitterlinden AG, van Leeuwen JPTM, Pols HA. 2001. Genetics and genomics of osteoporosis. In: Marcus R, Feldman D, Kelsey J, editors. Osteoporosis. San Diego: Academic Press. pp 639-667.
44. Young MR, Ihm J, Lozano Y, Wright MA, Prechel MM. 1995. Treating tumor-bearing mice with vitamin D3 diminishes tumor-induced myelopoiesis and associated immunosuppression, and reduces tumor metastasis and recurrence. Cancer Immunol Immunother 41:37-45.
45. Zhang XH, Jin L, Sakamoto H, Takenaka I. 1996. Immunohistochemical localization of metallothionein in human prostate cancer. J Urol 156:1679-1681.
46. Zhao XY, Ly LH, Peehl DM, Feldman D. 1997. 1alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent. Endocrinology 138:3290-3298.
47. Zhao XY, Ly LH, Peehl DM, Feldman D. 1999. Induction of androgen receptor by 1alpha,25-dihydroxyvitamin D3 and 9-cis retinoic acid in LNCaP human prostate cancer cells. Endocrinology 140:1205-1212.
48. Zhao XY, Peehl DM, Navone NM, Feldman D. 2000. 1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms. Endocrinology 141:2548-2556.
49. Zhuang SH, Burnstein KL. 1998. Antiproliferative effect of 1alpha,25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation. Endocrinology 139:1197-1207.